International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 68

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in *Cumulative List No. 14, 2011* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 68

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans la *Liste récapitulative No. 14, 2011* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 68

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran reunidas en *Cumulative List No. 14, 2011* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

acidum deoxycholicum

deoxycholic acid

3α,12α-dihydroxy-5β-cholan-24-oic acid

acide désoxycholique

acide 3α,12α-dihydroxy-5β-cholan-24-oïque

ácido desoxicólico

ácido 3α,12α-dihidroxi-5β-colan-24-oico

$C_{24}H_{40}O_4$



acidum florilglutamicum (^{18}F)

florilglutamic acid (^{18}F)

(4*S*)-4-(3-[^{18}F]fluoropropyl)-L-glutamic acid

acide florilglutamique (^{18}F)

acide (4*S*)-4-(3-[^{18}F]fluoropropyl)-L-glutamique

ácido florilglútamico (^{18}F)

ácido (4*S*)-4-(3-[^{18}F]fluoropropil)-L-glutámico

$C_8H_{14}{}^{18}FNO_4$



acidum tiazoticum

tiazotic acid

[(5-methyl-1*H*-1,2,4-triazol-3-yl)sulfanyl]acetic acid

acide tiazotique

acide [(5-méthyl-1*H*-1,2,4-triazol-3-yl)sulfanyl]acétique

ácido tiazótico

ácido [(5-metil-1*H*-1,2,4-triazol-3-il)sulfanil]acético

$C_5H_7N_3O_2S$



amitifadinum

amitifadine (1*R*,5*S*)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane

amitifadine (1*R*,5*S*)-1-(3,4-dichlorophényl)-3-azabicyclo[3.1.0]hexane

amitifadina (1*R*,5*S*)-1-(3,4-diclorofenil)-3-azabiciclo[3.1.0]hexano

$C_{11}H_{11}Cl_2N$



bamosiranum

bamosiran siRNA inhibitor of β_2-adrenergic receptor production;
RNA duplex of cytidylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-thymidylyl-(3'→5')-thymidine with thymidylyl-(5'→3')-thymidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidine

bamosiran petit ARN interférant (siRNA) inhibiteur de la production du récepteur adrénergique β_2;
duplex ARN du brin cytidylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-thymidylyl-(3'→5')-thymidine avec le brin anti-sens thymidylyl-(5'→3')-thymidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidine

bamosirán ARN interferente pequeño (siRNA) inhibidor de la producción del receptor adrenérgico β_2
ARN dúplex de la cadena citidilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-timidilil-(3'→5')-timidina con la cadena antisentido timidilil-(5'→3')-timidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-uridilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-citidina

$C_{401}H_{500}N_{150}O_{290}P_{40}$

(3'-5')CAUUGUGCAUGUGAUCCAG-dT-dT
(5'-3')dT-dT-GUAACACGUACACUAGGUC

brexpiprazolum

brexpiprazole — 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1*H*)-one

brexpiprazole — 7-{4-[4-(1-benzothiophén-4-yl)pipérazin-1-yl]butoxy}quinoléin-2(1*H*)-one

brexpiprazol — 7-{4-[4-(1-benzotiofen-4-il)piperazin-1-il]butoxi}quinolin-2(1*H*)-ona

$C_{25}H_{27}N_3O_2S$



buparlisibum

buparlisib — 5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine

buparlisib — 5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluorométhyl)pyridin-2-amine

buparlisib — 5-[2,6-bis(morfolin-4-il)pirimidin-4-il]-4-(trifluorometil)piridin-2-amina

$C_{18}H_{21}F_3N_6O_2$



camicinalum

camicinal — 1-{4-[(3-fluorophenyl)amino]piperidin-1-yl}-2-(4-{[(3*S*)-3-methylpiperazin-1-yl]methyl}phenyl)ethan-1-one

camicinal — 1-{4-[(3-fluorophényl)amino]pipéridin-1-yl}-2-(4-{[(3*S*)-3-méthylpipérazin-1-yl]méthyl}phényl)éthan-1-one

camicinal — 1-{4-[(3-fluorofenil)amino]piperidin-1-il}-2-(4-{[(3*S*)-3-metilpiperazin-1-il]metil}fenil)etan-1-ona

$C_{25}H_{33}FN_4O$



caplacizumabum #

caplacizumab — immunoglobulin VH-linker-VH fragment, anti-[*Homo sapiens* VWF (von Willebrand factor) A1 domain], humanized monoclonal antibody;
VH-linker-VH chain (1-259) [humanized VH (*Homo sapiens* IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)] -trialanyl linker (129-131) -[humanized VH (*Homo sapiens* IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)

caplacizumab — immunoglobuline fragment VH-linker-VH, anti-[*Homo sapiens* VWF (facteur de von Willebrand) domaine A1], anticorps monoclonal humanisé;
chaîne VH-linker-VH (1-259) [VH humanisé (*Homo sapiens* IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)] -trialanyl linker (129-131) -[VH humanisé (*Homo sapiens* IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)

caplacizumab — inmunoglobulina fragmento VH-conector-VH, anti-[VWF (factor de von Willebrand) de *Homo sapiens* dominio A1], anticuerpo monoclonal humanizado;
cadena VH-conector-VH (1-259) [VH humanizado (*Homo sapiens* IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)] -trialanil conector (129-131) -[VH humanizado (*Homo sapiens* IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)

```
EVQLVESGGG LVQPGGSLRL SCAASGRTFS YNPMGWFRQA PGKGRELVAA  50
ISRTGGSTYY PDSVEGRFTI SRDNAKRMVY LQMNSLRAED TAVYYCAAAG 100
VRAEDGRVRT LPSEYTFWGQ GTQVTVSSAA AEVQLVESGG GLVQPGGSLR 150
LSCAASGRTF SYNPMGWFRQ APGKGRELVA AISRTGGSTY YPDSVEGRFT 200
ISRDNAKRMV YLQMNSLRAE DTAVYYCAAA GVRAEDGRVR TLPSEYTFWG 250
QGTQVTVSS                                              259
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain 22-96 153-227

cerlapirdinum

cerlapirdine — *N*,*N*-dimethyl-3-{[3-(naphthalene-1-sulfonyl)-1*H*-indazol-5-yl]oxy}propan-1-amine

cerlapirdine — *N*,*N*-diméthyl-3-{[3-(naphtaléne-1-sulfonyl)-1*H*-indazol-5-yl]oxy}propan-1-amine

cerlapirdina — *N*,*N*-dimetil-3-{[3-(naftaleno-1-sulfonil)-1*H*-indazol-5-il]oxi}propan-1-amina

$C_{22}H_{23}N_3O_3S$



dexmecamylaminum

dexmecamylamine — (1*R*,2*S*,4*S*)-*N*,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine

dexmécamylamine — (1*R*,2*S*,4*S*)-*N*,2,3,3-tétraméthylbicyclo[2.2.1]heptan-2-amine

dexmecamilamina — (1*R*,2*S*,4*S*)-*N*,2,3,3-tetrametilbiciclo[2.2.1]heptan-2-amina



drisapersenum

drisapersen

all-P-ambo-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-methyluridine

drisapersen

tout-P-ambo-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-méthyluridine

drisapersén

todo-P-ambo-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-*O*-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-metil-*P*-tioadenilil-(3'→5')-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-*O*-metil-*P*-tiouridilil-(3'→5')-2'-*O*-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-metiluridina

$C_{211}H_{275}N_{76}O_{119}P_{19}S_{19}$

(3'-5')(P-thio)(Um-Cm-Am-Am-Gm-Gm-Am-Am-Gm-Am-Um-Gm-Gm-Cm-Am-Um-Um-Um-Cm-Um)

faldaprevirum

faldaprevir

(1*R*,2*S*)-1-{[(2*S*,4*R*)-4-[{8-bromo-7-methoxy-2-[2-(2-methylpropanamido)-1,3-thiazol-4-yl]quinolin-4-yl}oxy]-1-[(2*S*)-2-{[(cyclopentyloxy)carbonyl]amino}-3,3-dimethylbutanoyl]pyrrolidine-2-carboxamido}-2-ethenylcyclopropane-1-carboxylic acid

faldaprévir

acide (1*R*,2*S*)-1-{[(2*S*,4*R*)-4-[{8-bromo-7-méthoxy-2-[2-(2-méthylpropanamido)-1,3-thiazol-4-yl]quinoléin-4-yl}oxy]-1-[(2*S*)-2-{[(cyclopentyloxy)carbonyl]amino}-3,3-diméthylbutanoyl]pyrrolidine-2-carboxamido}-2-éthénylcyclopropane-1-carboxylique

faldaprevir

ácido (1*R*,2*S*)-1-{[(2*S*,4*R*)-4-[{8-bromo-7-methoxy-2-[2-(2-metilpropanamido)-1,3-tiazol-4-il]quinolin-4-il}oxi]-1-[(2*S*)-2-{[(ciclopentiloxi)carbonil]amino}-3,3-dimetilbutanoil]pirrolidina-2-carboxamido}-2-etenilciclopropano-1-carboxílico

$C_{40}H_{49}BrN_6O_9S$



flanvotumabum #

flanvotumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* TYRP1 (tyrosinase-related protein 1, 5,6-dihydroxyindole-2-carboxylic acid oxidase, DHICA oxidase, TRP1, melanoma antigen gp75)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV7-4-1*02 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer

flanvotumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* TYRP1 (protéine 1 apparentée à la tyrosinase, oxydase de l'acide 5,6-dihydroxyindole-2-carboxylique, DHICA-oxydase, TRP1, antigène gp75 du mélanome)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV7-4-1*02 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure

flanvotumab

inmunoglobulina G1-kappa, anti-[TYRP1 de *Homo sapiens* (proteina 1 relacionada con la tirosinasa), oxidasa del ácido 5,6-dihidroxiindol-2-carboxílico, DHICA-oxidasa, TRP1, antígeno gp75 de melanoma)], anticuerpo monoclonal *de Homo sapiens*;
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV7-4-1*02 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGSE LKKPGASVKI SCKASGYTFT SYAMNWVRQA PGQGLESMGW  50
INTNTGNPTY AQGFTGRFVF SMDTSVSTAY LQISSLKAED TAIYYCAPRY 100
SSSWYLDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWLMYTFG 100
QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L 23'-88' 135'-195'
23'"-88'" 135'"-195'"
Inter-H-L 222-215' 222"-215'"
Inter-H-H 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

follitropinum gamma #

follitropin gamma

heterodimer of human glycoprotein hormones alpha chain and follitropin subunit beta (FSH-beta), follicle stimulating hormone, glycoform gamma

follitropine gamma

hétérodimère constitué de la chaîne alpha des hormones glycoprotéiques et de la sous-unité bêta de la follitropine (FSH-bêta) humaines, hormone folliculostimulante, forme glycosylée gamma

folitropina gamma

heterodímero formado por la cadena alfa de las hormonas glicoprotéicas y la subunidad beta de la folitropina (FSH-beta) humanas, hormona estimulante del folículo, forma glicosilada gamma

$C_{975}H_{1493}N_{267}O_{305}S_{26}$ (peptide)

Alpha subunit / Sous-unité alpha / Subunidad alfa

```
APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP LRSKKTMLVQ  50
KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACHCSTCYYH KS          92
```

Beta subunit / Sous-unité bêta / Subunidad beta

```
NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPARPKIQKT 50'
CTFKELVYET VRVPGCAHHA DSLYTYPVAT QCHCGKCDSD STDCTVRGLG 100'
PSYCSFGEMK E                                           111'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
7-31 10-60 28-82 32-84 59-87
3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-7' Asn-24' Asn-52 Asn-78



R = α-Fuc or H, R3 = α-Sia or H, R4 and R6 = R3→3-β-Gal→4-β-Gl-*N* or H

gemcitabini elaidas
gemcitabine elaidate — 2'-deoxy-2',2'-difluorocytidine 5'-(9*E*)-octadec-9-enoate

élaïdate de gemcitabine — 5'-(9*E*)-octadéc-9-énoate de 2'-déoxy-2',2'-difluorocytidine

elaidato de gemcitabina — 5'-(9*E*)-octadec-9-enoato de 2'-desoxi-2',2'-difluorocitidina

$C_{27}H_{43}F_2N_3O_5$



glyceroli phenylbutyras
glycerol phenylbutyrate — propane-1,2,3-triyl tris(4-phenylbutanoate)

phénylbutyrate de glycérol — tris(4-phénylbutanoate) de propane-1,2,3-triyle

fenilbutirato de glicerol — tris(4-fenilbutanoato) de propano-1,2,3-triilo

$C_{33}H_{38}O_6$



idursulfasum beta #
idursulfase beta — iduronate 2-sulfatase (α-L-iduronate sulfate sulfatase), human pro-enzyme produced in CHO cells (glycoform beta)

idursulfase bêta — iduronate 2-sulfatase (α-L-iduronate sulfate sulfatase), proenzyme humaine produite par des cellules CHO (glycoforme bêta)

idursulfasa beta — iduronato 2-sulfatasa (α-L-iduronato sulfato sulfatasa), proenzima humana producida por células CHO (forma glicosilada beta)

$C_{2689}H_{4051}N_{699}O_{793}S_{13}$

```
SETQANSTTD ALNVLLIIVD DLRPSLGCYG DKLVRSPNID QLASHSLLFQ 50
NAFAQQAVCA PSRVSFLTGR RPDTTRLYDF NSYWRVHAGN FSTIPQYFKE 100
NGYVTMSVGK VFHPGISSNH TDDSPYSWSF PPYHPSSEKY ENTKTCRGPD 150
GELHANLLCP VDVLDVPEGT LPDKQSTEQA IQLLEKMKTS ASPFFLAVGY 200
HKPHIPFRYP KEFQKLYPLE NITLAPDPEV PDGLPPVAYN PWMDIRQRED 250
VQALNISVPY GPIPVDFQRK IRQSYFASVS YLDTQVGRLL SALDDLQLAN 300
STIIAFTSDH GWALGEHGEW AKYSNFDVAT HVPLIFYVPG RTASLPEAGE 350
KLFPYLDPFD SASQLMEPGR QSMDLVELVS LFPTLAGLAG LQVPPRCPVP 400
SFHVELCREG KNLLKHFRFR DLEEDPYLPG NPRELIAYSQ YPRPSDIPQW 450
NSDKPSLKDI KIMGYSIRTI DYRYTVWVGF NPDEFLANFS DIHAGELYFV 500
DSDPLQDHNM YNDSQGGDLF QLLMP                            525
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
146-159 397-407

Modified residue / Résidu modifié / Residuo modificado

C
59
3-oxoAla



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-6 Asn-90 Asn-119 Asn-221 Asn-255 Asn-300 Asn-488 Asn-512

inclacumabum #

inclacumab	immunoglobulin G4-kappa, anti-[*Homo sapiens* SELP (selectin P, CD62)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-13*01 (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 hinge S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (230-230'':233-233'')-bisdisulfide dimer
inclacumab	immunoglobuline G4-kappa, anti-[*Homo sapiens* SELP (sélectine P, CD62)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-451) [*Homo sapiens* VH (IGHV3-13*01 (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 charnière S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (230-230'':233-233'')-bisdisulfure
inclacumab	inmunoglobulina G4-kappa, anti-[SELP de *Homo sapiens* (selectina P, CD62)], anticuerpo monoclonal de *Homo sapiens* ; cadena pesada gamma4 (1-451) [*Homo sapiens* VH (IGHV3-13*01 (94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 bisagra S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (230-230'':233-233'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVRPGGSLRL SCAASGFTFS NYDMHWVRQA TGKGLEWVSA  50
ITAAGDIYYP GSVKGRFTIS RENAKNSLYL QMNSLRAGDT AVYYCARGRY 100
SGSGSYYNDW FDPWGQGTLV TVSSASTKGP SVFPLAPCSR STSESTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTKTYTCNVD HKPSNTKVDK RVESKYGPPC PPCPAPEFEG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN AKTKPREEQF 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI SKAKGQPREP 350
QVYTLPPSQE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSRLTVDKSR WQEGNVFSCS VMHEALHNHY TQKSLSLSLG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-95 151-207 265-325 371-429
22"-95" 151"-207" 265"-325" 371"-429"
Intra-L 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L 138-214' 138"-214'"
Inter-H-H 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
301, 301"

lucerastatum

lucerastat — (2*R*,3*S*,4*R*,5*S*)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol

lucérastat — (2*R*,3*S*,4*R*,5*S*)-1-butyl-2-(hydroxyméthyl)pipéridine-3,4,5-triol

lucerastat — (2*R*,3*S*,4*R*,5*S*)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol

$C_{10}H_{21}NO_4$



naltalimidum

naltalimide — 2-[17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6β-yl]isoindole-1,3-dione

naltalimide — 2-[-17-(cyclopropylméthyl)-4,5α-époxy-3,14-dihydroxymorphinan-6β-yl]-2*H*-isoindole-1,3-dione

naltalimida — 2-[17-(ciclopropilmetil)-4,5α-epoxi-3,14-dihidroximorfinan-6β-il]isoindol-1,3-diona

$C_{28}H_{28}N_2O_5$



netazepidum

netazepide	1-[(3*R*)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1*H*-1,4-benzodiazepin-3-yl]-3-[3-(methylamino)phenyl]urea
nétazépide	1-[(3*R*)-1-(3,3-diméthyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1*H*-1,4-benzodiazépin-3-yl]-3-[3-(méthylamino)phényl]urée
netazepida	1-[(3*R*)-1-(3,3-dimetil-2-oxobutil)-2-oxo-5-(piridin-2-il)-2,3-dihidro-1*H*-1,4-benzodiazepin-3-il]-3-[3-(metilamino)fenil]urea

$C_{28}H_{30}N_6O_3$



niraparibum

niraparib	2-{4-[(3*S*)-piperidin-3-yl]phenyl}-2*H*-indazole-7-carboxamide
niraparib	2-{4-[(3*S*)-pipéridin-3-yl]phényl}-2*H*-indazole-7-carboxamide
niraparib	2-{4-[(3*S*)-piperidin-3-il]fenil}-2*H*-indazol-7-carboxamida

$C_{19}H_{20}N_4O$



ondelopranum

ondelopran — 6-[2-fluoro-4-({[2-(oxan-4-yl)ethyl]amino}methyl)phenoxy]pyridine-3-carboxamide

ondélopran — 6-[2-fluoro-4-({[2-(oxan-4-yl)éthyl]amino}méthyl)phénoxy]pyridine-3-carboxamide

ondeloprán — 6-[2-fluoro-4-({[2-(oxan-4-il)etil]amino}metil)fenoxi]piridina-3-carboxamida

$C_{20}H_{24}FN_3O_3$



patiromerum calcium

patiromer calcium — cross-linked polymer of calcium 2-fluoroprop-2-enoate with diethenylbenzene and octa-1,7-diene

patiromère calcique — polymère réticulé de 2-fluoroprop-2-énoate de calcium avec du diéthénylbenzène et de l'octa-1,7-diène

patirómero cálcico — polímero reticulado de 2-fluoroprop-2-enoato de calcio con dietenilbenceno y octa-1,7-dieno

$[[(C_3H_2FO_2)_2\ Ca]_9\ [C_8H_{14}]\ [C_{10}H_{10}]]_n$



patritumabum #

patritumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-447) [*Homo sapiens* VH (IGHV4-34*01 (99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)], (220-220')-disulfide with kappa light chain (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-113') -IGKC*01 (114'-220')]; (226-226'':229-229'')-bisdisulfide dimer

patritumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB3 (récepteur tyrosine-protéine kinase erbB3, HER3)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-447) [*Homo sapiens* VH (IGHV4-34*01 (99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)], (220-220')-disulfure avec la chaîne légère kappa (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-113') -IGKC*01 (114'-220')]; dimère (226-226'':229-229'')-bisdisulfure

patritumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor de tirosina-proteina kinasa erbB3, HER3)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-447) [*Homo sapiens* VH (IGHV4-34*01 (99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)], (220-220')-disulfuro con la cadena ligera kappa (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-113') -IGKC*01 (114'-220')]; dímero (226-226'':229-229'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE  50
INHSGSTNYN PSLKSRVTIS VETSKNQFSL KLSSVTAADT AVYYCARDKW 100
TWYFDLWGRG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIEMTQSPDS LAVSLGERAT INCRSSQSVL YSSSNRNYLA WYQQNPGQPP  50
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYYST 100
PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-95    144-200    261-321    367-425
         22''-95''  144''-200''  261''-321''  367''-425''
Intra-L  23'-94'   140'-200'
         23'''-94''' 140'''-200'''
Inter-H-L  220-220'  220''-220'''
Inter-H-H  226-226'' 229-229''
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
297, 297''

plazomicinum

plazomicin

(2*S*)-4-amino-*N*-[(1*R*,2*S*,3*S*,4*R*,5*S*)-5-amino-4-{[(2*S*,3*R*)-3-amino-6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2*H*-pyran-2-yl]oxy}-2-{[3-deoxy-4-*C*-methyl-3-(methylamino)-β-L-arabinopyranosyl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide

plazomicine

(2*S*)-4-amino-*N*-[(1*R*,2*S*,3*S*,4*R*,5*S*)-5-amino-4-{[(2*S*,3*R*)-3-amino-6-{[(2-hydroxyéthyl)amino]méthyl}-3,4-dihydro-2*H*-pyran-2-yl]oxy}-2-{[3-déoxy-4-*C*-méthyl-3-(méthylamino)-β-L-arabinopyranosyl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide

plazomicina

(2*S*)-4-amino-*N*-[(1*R*,2*S*,3*S*,4*R*,5*S*)-5-amino-4-{[(2*S*,3*R*)-3-amino-6-{[(2-hidroxietil)amino]metil}-3,4-dihidro-2*H*-piran-2-il]oxi}-2-{[3-desoxi-4-*C*-metil-3-(metilamino)-β-L-arabinopiranosil]oxi}-3-hidroxiciclohexil]-2-hidroxibutanamida

$C_{25}H_{48}N_6O_{10}$



pradigastatum

pradigastat

{(1*r*,4*r*)-4-[4-(5-{[6-(trifluoromethyl)pyridin-3-yl]amino}pyridin-2-yl)phenyl]cyclohexyl}acetic acid

pradigastat — acide {*trans*-4-[4-(5-{[6-(trifluorométhyl)pyridin-3-yl]amino}pyridin-2-yl)phényl]cyclohexyl}acétique

pradigastat — ácido {(1*r*,4*r*)-4-[4-(5-{[6-(trifluorometil)piridin-3-il]amino}piridin-2-il) fenil]ciclohexil}acético

$C_{25}H_{24}F_3N_3O_2$



pritelivirum

pritelivir — *N*-methyl-*N*-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phenyl]acetamide

pritélivir — *N*-méthyl-*N*-(4-méthyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-2-yl)phényl]acétamide

pritelivir — *N*-metil-*N*-(4-metil-5-sulfamoil-1,3-tiazol-2-il)-2-[4-(pyridin-2-il)fenil]acetamida

$C_{18}H_{18}N_4O_3S_2$



quilizumabum #

quilizumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* IGHE connecting region (CO) M1 prime (in alternatively spliced heavy chain of membrane IgE on B cells)], humanized monoclonal antibody; gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 CH1 R120>K (214) (118-447)], (220-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (226-226":229-229")-bisdisulfide dimer

quilizumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* IGHE région de connexion (CO) M1 prime (dans la chaîne lourde des IgE membranaires à la surface des lymphocytes B, épissée de manière alternative)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 CH1 R120>K (214) (118-447)], (220-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (226-226":229-229")-bisdisulfure

quilizumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IGHE región de conexión (CO) M1 prime (en la cadena pesada de las IgE de membrana de la superficie de los linfocitos B, ensamblada de modo alternativo)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03 CH1 R120>K (214) (118-447)], (220-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYGIAWVRQA PGKGLEWVAF  50
ISDLAYTIYY ADTVTGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDN 100
WDAMDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRSSQSLV HNNANTYLHW YQQKPGKAPK  50
LLIYKVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCSQNTLVP 100
WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96     144-200    261-321    367-425
          22"-96"   144"-200"  261"-321"  367"-425"
Intra-L   23'-93'    139'-199'
          23'"-93'"  139'"-199'"
Inter-H-L 220-219'   220"-219'"
Inter-H-H 226-226"   229-229"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
297, 297" (non-fucosylated oligosaccharides)

radavirsenum

radavirsen

all-P-ambo-P,2',3'-trideoxy-*P*-(dimethylamino)-5'-*O*-{*P*-[4-({2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-*N*,*N*-dimethylphosphonamidoyl}-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-(2'a→5')-*P*,3'-dideoxy-*P*-(piperazin-1-yl)-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,3'-dideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-(piperazin-1-yl)-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,3'-dideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-*P*,3'-dideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,2',3'-trideoxy-*P*-(piperazin-1-yl)-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-*P*,3'-dideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,3'-dideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secothymidylyl-(2'a→5')-*P*,3'-dideoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-secothymidine

radavirsen	*tout-P-ambo-P*,2',3'-tridéoxy-*P*-(diméthylamino)-5'-*O*-{*P*-[4-({2-[2-(2-hydroxyéthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-*N*,*N*-diméthylphosphonamidoyl}-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-*P*,3'-didéoxy-2',3'-imino-*P*-(pipérazin-1-yl)-2',3'-sécothymidylyl-(2'a→5')-*P*,3'-didéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécoadenylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,2',3'-tridéoxy-2',3'-imino-*P*-(pipérazin-1-yl)-2',3'-sécocytidylyl-(2'a→5')-*P*,3'-didéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-*P*,2',3'-tridéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-*P*,3'-didéoxy-*P*-(dimethylamino)-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,2',3'-tridéoxy-2',3'-imino-*P*-(pipérazin-1-yl)-2',3'-sécocytidylyl-(2'a→5')-*P*,3'-didéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-*P*,3'-didéoxy-*P*-(diméthylamino)-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-3'-déoxy-2',3'-imino-2',3'-sécothymidine
radavirsén	*todo-P-ambo-P*,2',3'-tridesoxi-*P*-(dimetilamino)-5'-*O*-{*P*-[4-({2-[2-(2-hidroxietoxi)etoxi]etoxi}carbonil)piperazin-1-il]-*N*,*N*-dimetilfosfonamidoil}-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a→5')-*P*,3'-didesoxi-*P*-(piperazin-1-il)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,3'-didesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(piperazin-1-il)-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,3'-didesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-*P*,3'-didesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,2',3'-tridesoxi-*P*-(piperazin-1-il)-2',3'-imino-2',3'-secocitidilil-(2'a→5')-*P*,3'-didesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,3'-didesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-*P*,3'-didesoxi-*P*-(dimetilamino)-2',3'-imino-2',3'-secotimidina

$C_{253}H_{398}N_{116}O_{87}P_{20}$



B(1-20) : C-G-G-T-T-A-G-A-A-G-A-C-T-C-A-T-C-T-T-T

R(1-3) = R(5-11) = R(13-16) = R(18) = R(19) = $-N(CH_3)_2$

R(4) = R(12) = R(17) = 

rafigrelidum

rafigrelide — 6,7-dichloro-3,3-dimethyl-5,10-dihydroimidazo[2,1-*b*]quinazolin-2(3*H*)-one

rafigrélide — 6,7-dichloro-3,3-diméthyl-1,5-dihydroimidazo[2,1-*b*]quinazolin-2(3*H*)-one

rafigrelida — 6,7-dicloro-3,3-dimetil-5,10-dihidroimidazo[2,1-*b*]quinazolin-2(3*H*)-ona

$C_{12}H_{11}Cl_2N_3O$



refametinibum

refametinib — *N*-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[(2*S*)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide

réfamétinib — *N*-{3,4-difluoro-2-[(2-fluoro-4-iodophényl)amino]-6-méthoxyphényl}-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide

refametinib — *N*-{3,4-difluoro-2-[(2-fluoro-4-iodofenil)amino]-6-metoxifenil}-1-[(2*S*)-2,3-dihidroxipropil]ciclopropano-1-sulfonamida

$C_{19}H_{20}F_3IN_2O_5S$



rigosertibum

rigosertib — *N*-[2-methoxy-5-({[(1*E*)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine

rigosertib — *N*-[2-méthoxy-5-({[(1*E*)-2-(2,4,6-triméthoxyphényl)éthényl]sulfonyl}méthyl)phényl]glycine

rigosertib — *N*-[2-metoxi-5-({[(1*E*)-2-(2,4,6-trimetoxifenil)etenil]sulfonil}metil)fenil]glicina

$C_{21}H_{25}NO_8S$



riodipinum

riodipine — dimethyl 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

riodipine — 4-[2-(difluorométhoxy)phényl]-2,6-diméthyl-1,4-dihydropyridine-3,5-dicarboxylate de diméthyle

riodipino — 4-[2-(difluorometoxi)fenil]-2,6-dimetil-1,4-dihidropiridina-3,5-dicarboxilato de dimetilo

$C_{18}H_{19}F_2NO_5$



romosozumabum #

romosozumab — immunoglobulin G2-kappa, anti-[*Homo sapiens* SOST (sclerostin)], humanized monoclonal antibody;
gamma2 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T (118) [8.8.16] (1-123) -*Homo sapiens* IGHG2*01 (124-449)], (137-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (225-225":226-226":229-229":232-232")-tetrakisdisulfide dimer

romosozumab — immunoglobuline G2-kappa, anti-[*Homo sapiens* SOST (sclérostine)], anticorps monoclonal humanisé;
chaîne lourde gamma2 (1-449) [VH humanisé (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T (118) [8.8.16] (1-123) -*Homo sapiens* IGHG2*01 (124-449)], (137-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (225-225":226-226":229-229":232-232")-tétrakisdisulfure

romosozumab

inmunoglobulina G2-kappa, anti-[SOST (esclerostina) de *Homo sapiens*], anticuerpo monoclonal humanizado;
cadena pesada gamma2 (1-449) [VH humanizado (*Homo sapiens* IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T (118) [8.8.16] (1-123) -*Homo sapiens* IGHG2*01 (124-449)], (137-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (225-225":226-226":229-229":232-232")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGASVKV SCKASGYTFT DYNMHWVRQA PGQGLEWMGE  50
INPNSGGAGY NQKFKGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARLG 100
YDDIYDDWYF DVWGQGTTVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSNFG 200
TQTYTCNVDH KPSNTKVDKT VERKCCVECP PCPAPPVAGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TFRVVSVLTV VHQDWLNGKE YKCKVSNKGL PAPIEKTISK TKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPML 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQDIS NYLNWYQQKP GKAPKLLIYY  50
TSRLLSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GDTLPYTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 150-206 263-323 369-427
22"-96" 150"-206" 263"-323" 369"-427"
Intra-L 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L 137-214' 137"-214'"
Inter-H-H 225-225" 226-226" 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

samidorphanum

samidorphan

17-(cyclopropylmethyl)-4,14-dihydroxy-6-oxomorphinan-3-carboxamide

samidorphan

17-(cyclopropylméthyl)-4,14-dihydroxy-6-oxomorphinane-3-carboxamide

samidorfano

17-(ciclopropilmetil)-4,14-dihidroxi-6-oxomorfinan-3-carboxamida

$C_{21}H_{26}N_2O_4$



sapitinibum

sapitinib

2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]-*N*-methylacetamide

sapitinib

2-[4-({4-[(3-chloro-2-fluorophényl)amino]-7-méthoxyquinazolin-6-yl}oxy)pipéridin-1-yl]-*N*-méthylacétamide

sapitinib

2-[4-({4-[(3-cloro-2-fluorofenil)amino]-7-metoxiquinazolin-6-il}oxi)piperidin-1-il]-*N*-metilacetamida

$C_{23}H_{25}ClFN_5O_3$



sarilumabum #

sarilumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL6R (interleukin 6 receptor, IL-6R, CD126)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-9*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (225-225":228-228")-bisdisulfide dimer

sarilumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL6R (récepteur de l'interleukine 6, IL-6R, CD126)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV3-9*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)], (219-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-225":228-228")-bisdisulfure

sarilumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL6R (receptor de la interleukina 6, IL-6R, CD126)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV3-9*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGRSLRL SCAASRFTFD DYAMHWVRQA PGKGLEWVSG  50
ISWNSGRIGY ADSVKGRFTI SRDNAENSLF LQMNGLRAED TALYYCAKGR 100
DSFDIWGQGT MVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS VSASVGDRVT ITCRASQGIS SWLAWYQQKP GKAPKLLIYG  50
ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFASYYCQQ ANSFPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	143-199	260-320	366-424
	22"-96"	143"-199"	260"-320"	366"-424"
Intra-L	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L	219-214'	219"-214'"		
Inter-H-H	225-225"	228-228"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
296, 296"

secretinum humanum

secretin human

human peptide hormone secretin;
L-histidyl-L-seryl-L-aspartylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-L-arginyl-L-glutamylglycyl-L-alanyl-Larginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide

sécrétine humaine

sécrétine humaine hormone peptidique;
L-histidyl-L-séryl-L-aspartylglycyl-L-thréonyl-L-phénylalanyl-L-thréonyl-L-séryl-L-glutamyl-L-leucyl-L-séryl-L-arginyl-L-leucyl-L-arginyl-L-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide

secretina humana

secretina humana, hormona peptídica;
L-histidil-L-seril-L-aspartilglicil-L-treonil-L-fenilalanil-L-treonil-L-seril-L-glutamil-L-leucil-L-seril-L-arginil-L-leucil-L-arginil-L-glutamilglicil-L-alanil-L-arginil-L-leucil-L-glutaminil-L-arginil-L-leucil-L-leucil-L-glutaminilglicil-L-leucil-L-valinamida

$C_{130}\ H_{220}\ N_{44}\ O_{40}$

HSDGTFTSEL SRLREGARLQ RLLQGLV 27

Modified residue / Résidu modifié / Residuo modificado

V
27
valinamide



selisistatum

selisistat

rac-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazole-1-carboxamide

sélisistat

rac-6-chloro-2,3,4,9-tétrahydro-1*H*-carbazole-1-carboxamide

selisistat

rac-6-cloro-2,3,4,9-tetrahidro-1*H*-carbazol-1-carboxamida

$C_{13}H_{13}ClN_2O$



and enantiomer
et énantiomère
y enantiómero

setrobuvirum

setrobuvir

N-(3-{(4a*R*,5*S*,8*R*,8a*S*)-1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ^6,2,4-benzothiadiazin-7-yl)methanesulfonamide

sétrobuvir

N-(3-{(4a*R*,5*S*,8*R*,8a*S*)-1-[(4-fluorophényl)méthyl]-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro-5,8-méthanoquinoléin-3-yl}-1,1-dioxo-1,4-dihydro-1λ^6,2,4-benzothiadiazin-7-yl)méthanesulfonamide

setrobuvir

N-(3-{(4a*R*,5*S*,8*R*,8a*S*)-1-[(4-fluorofenil)metil]-4-hidroxi-2-oxo-1,2,4a,5,6,7,8,8a-octahidro-5,8-metanoquinolin-3-il}-1,1-dioxo-1,4-dihidro-1λ^6,2,4-benzotiadiazin-7-il)metanosulfonamida

$C_{25}H_{25}FN_4O_6S_2$



sevuparinum natricum

sevuparin sodium — sodium salt of a low molecular mass heparin obtained by depolymerization through periodate oxidation of heparin from porcine intestinal mucosa, followed by reduction and mild acid hydrolysis of the product; the majority of the components have a 2-amino-2-deoxy-D-glucopyranose derivative structure at both ends of their chain, the one at the reducing end can be substituted with threonic acid or erythronic acid; the relative average molecular mass range is approximately 7,500 daltons with about 90% ranging between 2,000 and 15,000 daltons; the degree of sulfation is 2 to 2.5 per disaccharidic unit

sévuparine sodique — sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d'une oxydation periodique, d'héparine de muqueuse intestinale de porc, suivi par une réduction et par une hydrolyse douce; la majorité des composants de la sévuparine sodique possèdent une structure 2-amino-2-déoxy-D-glucopyranose aux deux extrémités, la réductrice peut être substituée par un acide thréonique ou érythronique; la masse moléculaire relative moyenne est approximativement de 7500 daltons, et celles de 90% sont comprises entre 2000 à 15000; le degré de sulfatation est de 2 à 2,5 par unité disaccharide.

sevuparina sódica — sal sódica de una heparina de baja masa molecular obtenida por despolimerización, mediante oxidación periodica, de heparina de mucosa intestinal porcina, seguida de reducción e hidrólisis con ácido débil; la mayoría de los componentes de la sevuparina sódica tienen una estructura 2-amino-2-desoxi-D-glucopiranosa en los dos extremos, el reductor puede estar substituido con un ácido treónico o eritrónico; la masa molecular relativa media es aproximadamente de 7500 dalton, y con el 90% comprendido entre 2000 y 15000; el grado de sulfatación es de 2 a 2,5 por unidad de disacárido

solitomabum #

solitomab — immunoglobulin scFv-scFv, anti-[*Homo sapiens* EPCAM (epithelial cell adhesion molecule, tumor-associated calcium signal transducer 1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP-2, KSA, KS1/4 antigen, M4S1, tumor antigen 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[*Homo sapiens* CD3E (CD3 epsilon)], *Mus musculus* monoclonal antibody bispecific single chain;
scFv anti-EPCAM [*Mus musculus* V-KAPPA (IGKV8-19*01 (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer tris(tetraglycyl-seryl) linker (114-128) -*Mus musculus* VH (IGHV1-54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-248)] -5-mer tetraglycyl-seryl linker (249-253) -scFv anti-CD3E [humanized VH (*Homo sapiens* IGHV1-46*01 (82.50%)-(IGHD)-IGHJ6*01) [8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA (*Mus musculus* IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9] (391-496)] -hexahistidine (497-502)

solitomab

immunoglobuline scFv-scFv, anti-[*Homo sapiens* EPCAM (molécule d'adhésion des cellules épithéliales, transducteur 1 du signal calcium associé aux tumeurs, TACSTD1, protéine 2 associée aux tumeurs gastrointestinales, GA733-2, glycoprotéine épithéliale 2, EGP-2, KSA, antigène KS1/4, M4S1, antigène tumoral 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[*Homo sapiens* CD3E (CD3 epsilon)], *Mus musculus* anticorps monoclonal bispécifique à chaîne unique;
scFv anti-EPCAM [*Mus musculus* V-KAPPA (IGKV8-19*01 (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer tris(tétraglycyl-séryl) linker (114-128) -*Mus musculus* VH (IGHV1-54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-248)] -5-mer tétraglycyl-séryl linker (249-253) -scFv anti-CD3E [VH humanisé (*Homo sapiens* IGHV1-46*01 (82.50%)-(IGHD)-IGHJ6*01) [8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA (*Mus musculus* IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9] (391-496)] -hexahistidine (497-502)

solitomab

inmunoglobulina scFv-scFv, anti-[EPCAM de *Homo sapiens* (molécula de adhesión de células epiteliales, transductor 1 de la señal de calcio asociado a tumores, TACSTD1, proteina 2 asociada a tumores gastrointestinales, GA733-2, glicoproteina epitelial 2, EGP-2, KSA, antígeno KS1/4, M4S1, antígeno tumoral 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[*Homo sapiens* CD3E (CD3 epsilon)], anticuerpo monoclonal biespecifico monocatenario de *Mus musculus*;
scFv anti-EPCAM [*Mus musculus* V-KAPPA (IGKV8-19*01 (98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer tris(tetraglicil-seril) conector (114-128) -*Mus musculus* VH (IGHV1-54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-248)] -5-mer tetraglicil-seril conector (249-253) -scFv anti-CD3E [VH humanizado (*Homo sapiens* IGHV1-46*01 (82.50%)-(IGHD)-IGHJ6*01) [8.8.12] (254-372) -18-mer conector (373-390) -V-KAPPA (*Mus musculus* IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9] (391-496)] -hexahistidina (497-502)

```
ELVMTQSPSS LTVTAGEKVT MSCKSSQSLL NSGNQKNYLT WYQQKPGQPP  50
KLLIYWASTR ESGVPDRFTG SGSGTDFTLT ISSVQAEDLA VYYCQNDYSY 100
PLTFGAGTKL EIKGGGGSGG GGSGGGGSEV QLLEQSGAEL VRPGTSVKIS 150
CKASGYAFTN YWLGWVKQRP GHGLEWIGDI FPGSGNIHYN EKFKGKATLT 200
ADKSSSTAYM QLSSLTFEDS AVYFCARLRN WDEPMDYWGQ GTTVTVSSGG 250
GGSDVQLVQS GAEVKKPGAS VKVSCKASGY TFTRYTMHWV RQAPGQGLEW 300
IGYINPSRGY TNYADSVKGR FTITTDKSTS TAYMELSSLR SEDTATYYCA 350
RYYDDHYCLD YWGQGTTVTV SSGEGTSTGS GGSGGSGGAD DIVLTQSPAT 400
LSLSPGERAT LSCRASQSVS YMNWYQQKPG KAPKRWIYDT SKVASGVPAR 450
FSGSGSGTDY SLTINSLEAE DAATYYCQQW SSNPLTFGGG TKVEIKHHHH 500
HH                                                      502
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain 23-94 151-225 275-349 413-477

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
305 (but Pro in 306)

sovaprevirum

sovaprevir

(2*S*,4*R*)-1-[(2*S*)-2-*tert*-butyl-4-oxo-4-(piperidin-1-yl)butanoyl]-*N*-{(1*R*,2*S*)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]pyrrolidine-2-carboxamide

sovaprévir

(2*S*,4*R*)-1-[(2*S*)-2-*tert*-butyl-4-oxo-4-(pipéridin-1-yl)butanoyl]-*N*-{(1*R*,2*S*)-1-[(cyclopropanesulfonyl)carbamoyl]-2-éthénylcyclopropyl}-4-[(7-méthoxy-2-phénylquinoléin-4-yl)oxy]pyrrolidine-2-carboxamide

sovaprevir

(2*S*,4*R*)-1-[(2*S*)-2-*terc*-butil-4-oxo-4-(piperidin-1-il)butanoil]-*N*-{(1*R*,2*S*)-1-[(ciclopropanosulfonil)carbamoil]-2-etenilciclopropil}-4-[(7-metoxi-2-fenilquinolin-4-il)oxi]pirrolidina-2-carboxamida

$C_{43}H_{53}N_5O_8S$



sutezolidum

sutezolid

N-({(5*S*)-3-[3-fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxo-1,3-oxazolan-5-yl}methyl)acetamide

sutézolid

N-({(5*S*)-3-[3-fluoro-4-(thiomorpholin-4-yl)phényl]-2-oxo-1,3-oxazolidin-5-yl}méthyl)acétamide

sutezolid

N-({(5*S*)-3-[3-fluoro-4-(tiomorfolin-4-il)fenil]-2-oxo-1,3-oxazolan-5-il}metil)acetamida

$C_{16}H_{20}FN_3O_3S$



tanzisertibum

tanzisertib

(1*r*,4*r*)-4-({9-[(3S)-oxolan-3-yl]-8-[(2,4,6-trifluorophenyl)amino]-9*H*-purin-2-yl}amino)cyclohexan-1-ol

tanzisertib

(1*r*,4*r*)-4-({9-[(3S)-oxolan-3-yl]-8-[(2,4,6-trifluorophényl)amino]-9*H*-purin-2-yl}amino)cyclohexan-1-ol

tanzisertib

(1*r*,4*r*)-4-({9-[(3S)-oxolan-3-il]-8-[(2,4,6-trifluorfenil)amino]-9*H*-purin-2-il}amino)ciclohexan-1-ol

$C_{21}H_{23}F_3N_6O_2$



tavaborolum

tavaborole	5-fluoro-2,1-benzoxaborol-1(3*H*)-ol
tavaborole	5-fluoro-2,1-benzoxaborol-1(3*H*)-ol
tavaborol	5-fluoro-2,1-benzoxaborol-1(3*H*)-ol

$C_7H_6BFO_2$



tedatioxetinum

tedatioxetine	4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
tédatioxétine	4-{2-[(4-méthylphényl)sulfanyl]phényl}pipéridine
tedatioxetina	4-{2-[(4-metilfenil)sulfanil]fenil}piperidina

$C_{18}H_{21}NS$



tipiracilum

tipiracil	5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1*H*,3*H*)-dione
tipiracil	5-chloro-6-[(2-iminopyrrolidin-1-yl)méthyl]pyrimidine-2,4-(1*H*,3*H*)-dione
tipiracilo	5-cloro-6-[(2-iminopirrolidin-1-il)metil]pirimidina-2,4-(1*H*,3*H*)-diona

$C_9H_{11}ClN_4O_2$



tirasemtivum

tirasemtiv — 6-ethynyl-1-(pentan-3-yl)-2*H*-imidazo[4,5-*b*]pyrazin-2-one

tirasemtiv — 6-éthynyl-1-(pentan-3-yl)-1,3-dihydro-2*H*-imidazo[4,5-b]pyrazin-2-one

tirasemtiv — 6-etinil-1-(pentan-3-il)-2*H*-imidazo[4,5-*b*]pirazin-2-ona

$C_{12}H_{14}N_4O$



tozadenantum

tozadenant — 4-hydroxy-*N*-[4-methoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]-4-methylpiperidine-1-carboxamide

tozadénant — 4-hydroxy-*N*-[4-méthoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]-4-méthylpipéridine-1-carboxamide

tozadenant — 4-hidroxi-*N*-[4-metoxi-7-(morfolin-4-il)-1,3-benzotiazol-2-il]-4-metilpiperidina-1-carboxamida

$C_{19}H_{26}N_4O_4S$



trebananibum #

trebananib — immunoglobulin G1 Fc fragment fused with two synthetic polypeptides that bind the *Homo sapiens* ANGPT2 (angiopoietin 2); methionyl (1) -gamma1 heavy chain fragment (2-228) [*Homo sapiens* IGHG1*01 hinge (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3 (122-228)] fused, at the C-terminal end, with a synthetic polypeptide that comprises two 14-mer amino acid repeats that bind angiopoietin 2 (229-287) [linker (229-235) -14-mer (236-249) -linker (250-271) -14-mer (272-285) -leucyl-glutamate]; (7-7':10-10')-bisdisulfide dimer

trébananib — immunoglobuline G1 fragment Fc fusionné à deux polypeptides synthétiques qui se lient à l'*Homo sapiens* ANGPT2 (angiopoïétine 2);
méthionyl (1) -fragment de chaîne gamma1 (2-228) [*Homo sapiens* IGHG1*01 charnière (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3 (122-228)] fusionné, à l'extrémité C-terminale, à un polypeptide synthétique qui comprend deux motifs répétés de 14 acides aminés qui se lient à l'angiopoïétine 2 (229-287) [linker (229-235) -14-mer (236-249) -linker (250-271) -14-mer (272-285) -leucyl-glutamate]; dimère (7-7':10-10')-bisdisulfure

trebananib

inmunoglobulina G1 fragmento Fc fusionado con dos polipéptidos sintéticos que se unen a la ANGPT2 (angiopoyetina 2) de *Homo sapiens*;
metionil (1) -fragmento de cadena gamma1 (2-228) [*Homo sapiens* IGHG1*01 bisagra (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3 (122-228)] fusionada con el extremo C-terminal de un polipéptido sintético que comprende dos secuencias repetidas de 14 aminoácidos que se unen a la angiopoyetina 2 (229-287) [conector (229-235) -14-mer (236-249) -conector (250-271) -14-mer (272-285) -leucil-glutamato]; dímero (7-7':10-10')-bisdisulfuro

```
MDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE  50
DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY 100
KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV 150
KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ 200
GNVFSCSVMH EALHNHYTQK SLSLSPGKGG GGGAQQEECE WDPWTCEHMG 250
SGSATGGSGS TASSGSGSAT HQEECEWDPW TCEHMLE               287
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain 42-102 148-206 239-246 275-282
42'-102' 148'-206' 239'-246' 275'-282'
Inter-chains 7-7' 10-10'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
78, 78'

trelagliptinum

trelagliptin

2-({6-[(3*R*)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl}methyl)-4-fluorobenzonitrile

trélagliptine

2-({6-[(3*R*)-3-aminopipéridin-1-yl]-3-méthyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl}méthyl)-4-fluorobenzonitrile

trelagliptina

2-({6-[(3*R*)-3-aminopiperidin-1-il]-3-metil-2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il}metil)-4-fluorobenzonitrilo

$C_{18}H_{20}FN_5O_2$



umeclidinii bromidum

umeclidinium bromide

1-{2-[(benzyl)oxy]ethyl}4-[hydroxydi(phenyl)methyl]-1-azabicyclo[2.2.2]octan-1-ium bromide

bromure d'uméclidinium

bromure de 1-{2-[(benzyl)oxy]éthyl}-4-[hydroxydi(phényl)méthyl]-1-azabicyclo[2.2.2]octanium

bromuro de umeclidinio

bromuro de 1-{2-[(bencil)oxi]etil}4-[hidroxidi(fenil)metil]-1-azabiciclo[2.2.2]octan-1-io

$C_{29}H_{34}BrNO_2$



vapendavirum

vapendavir	3-ethoxy-6-{2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy}-1,2-benzoxazole
vapendavir	3-éthoxy-6-{2-[1-(6-méthylpyridazin-3-yl)pipéridin-4-yl]éthoxy}-1,2-benzoxazole
vapendavir	3-etoxi-6-{2-[1-(6-metilpiridazin-3-il)piperidin-4-il]etoxi}-1,2-benzoxazol

$C_{21}H_{26}N_4O_3$



vonoprazanum

vonoprazan	1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1*H*-pyrrol-3-yl]-*N*-methylmethanamine
vonoprazan	1-[5-(2-fluorophényl)-1-(pyridine-3-sulfonyl)-1*H*-pyrrol-3-yl]-*N*-méthylméthanamine
vonoprazán	1-[5-(2-fluorofenil)-1-(piridina-3-sulfonil)-1*H*-pirrol-3-il]-*N*-metilmetanamina

$C_{17}H_{16}FN_3O_2S$



vortioxetinum

vortioxetine	1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine
vortioxétine	1-{2-[(2,4-diméthylphényl)sulfanyl]phényl}pipérazine
vortioxetina	1-{2-[(2,4-dimetilfenil)sulfanil]fenil}piperazina

$C_{18}H_{22}N_2S$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Non Proprietary Names (Rec. INN): List 17
(Chronicle of the WHO, 1977, Vol. 31, No. 10)

p. 7 **oxitropii bromidum**
oxitropium bromide *replace the description and the structure by the following ones*

(1*R*,2*R*,4*S*,5*S*,7*s*,9*s*)-9-ethyl-7-{[(2*S*)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.$0^{2,4}$]nonane bromide



Dénominations communes internationales recommandées (DCI Rec.): Liste 17
(Chronique de l'OMS, Vol. 31, No. 10, 1977)

p. 7 **oxitropii bromidum**
bromure d'oxitropium *remplacer la description et la structure par les suivantes*

bromure de (1*R*,2*R*,4*S*,5*S*,7*s*,9*s*)-9-éthyl-7-{[(2*S*)-3-hydroxy-2-phénylpropanoyl]oxy}-9-méthyl-3-oxa-9-azoniatricyclo[3.3.1.$0^{2,4}$]nonane



Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 17
(Crónica de la OMS, Vol. 31, No. 10, 1977)

p. 7 **oxitropii bromidum**
bromuro de oxitropio *sustitúyase la descripción y la estructura por las siguientes*

bromuro de (1*R*,2*R*,4*S*,5*S*,7*s*,9*s*)-9-etil-7-{[(2*S*)-2-fenil-3-hidroxipropanoil]oxi}-9-metil-3-oxa-9-azoniatriciclo[3.3.1.$0^{2,4}$]nonano



Recommended International Non Proprietary Names (Rec. INN): List 58
Dénominations communes internationales recommandées (DCI Rec.): Liste 58
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 58
(WHO Drug Information, Vol. 21, No. 3, 2007)

p. 260 **ulipristalum**

& 261 ulipristal — *replace the structure by the following*
ulipristal — *remplacer la structure par la suivante*
ulipristal — *sustitúyase la estructura por la siguiente*



Recommended International Non Proprietary Names (Rec. INN): List 60
Dénominations communes internationales recommandées (DCI Rec.): Liste 60
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 60
(WHO Drug Information, Vol. 22, No. 3, 2008)

p. 229 **conestatum alfa #**

conestat alfa — *replace the structure by the following*
conestat alfa — *remplacer la structure par la suivante*
conestat alfa — *sustitúyase la estructura por la siguiente*

```
NPNATSSSSQ DPESLQDRGE GKVATTVISK MLFVEPILEV SSLPTTNSTT  50
NSATKITANT TDEPTTQPTT EPTTQPTIQP TQPTTQLPTD SPTQPTTGSF 100
CPGPVTLCSD LESHSTEAVL GDALVDFSLK LYHAFSAMKK VETNMAFSPF 150
SIASLLTQVL LGAGENTKTN LESILSYPKD FTCVHQALKG FTTKGVTSVS 200
QIFHSPDLAI RDTFVNASRT LYSSSPRVLS NNSDANLELI NTWVAKNTNN 250
KISRLLDSLP SDTRLVLLNA IYLSAKWKTT FDPKKTRMEP FHFKNSVIKV 300
PMMNSKKYPV AHFIDQTLKA KVGQLQLSHN LSLVILVPQN LKHRLEDMEQ 350
ALSPSVFKAI MEKLEMSKFQ PTLLTLPRIK VTTSQDMLSI MEKLEFFDFS 400
YDLNLCGLTE DPDLQVSAMQ HQTVLELTET GVEAAAASAI SVARTLLVFE 450
VQQPFLFVLW DQQHKFPVFM GRVYDPRA                         478
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
101-406 108-183

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
Asn-3 Thr-26 Ser-42 Asn-47 Thr-49 Asn-59 Thr-61
Thr-66 Thr-70 Thr-74 Asn-216 Asn-231 Asn-330

Recommanded International Non Proprietary Names (Rec. INN): List 61
Denominations communes internationales recommandées (DCI Rec.): Liste 61
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 61
(WHO Drug Information, Vol. 23, No. 1, 2009)

p. 67 **macitentanum**

macitentan — *replace the chemical name by the following*

N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-*N'*-propylsulfuric diamide

Recommanded International Non Proprietary Names (Rec. INN): List 62
Denominations communes internationales recommandées (DCI Rec.): Liste 62
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62
(WHO Drug Information, Vol. 23, No. 3, 2009)

p. 263 & 264 **solanezumabum #**

solanezumab *replace the description and the structure by the following ones*
solanezumab *remplacer la description et la structure par les suivantes*
solanezumab *sustitúyase la descripción y la estructura por las siguientes*

immunoglobulin G1-kappa, anti-[*Homo sapiens* amyloid-beta (Abeta) peptide soluble monomer], humanized monoclonal antibody;
gamma1 heavy chain [humanized VH (*Homo sapiens* IGHV3-23*04 (87.60%) -(IGHD)-IGHJ4*01) [8.8.5] (1-112) -*Homo sapiens* IGHG1*01 (113-442)], (215-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (221-221":224-224")-bisdisulfide dimer

immunoglobuline G1-kappa, anti-[*Homo sapiens* amyloïde-bêta (Abeta) peptide monomère soluble], anticorps monoclonal humanisé;
chaîne lourde gamma1 [VH humanisé (*Homo sapiens* IGHV3-23*04 (87.60%) -(IGHD)-IGHJ4*01) [8.8.5] (1-112) -*Homo sapiens* IGHG1*01 (113-442)], (215-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (221-221":224-224")-bisdisulfure

inmunoglobulina G1-kappa, anti-[péptido amiloide-beta (Abeta) monomèrico soluble de *Homo sapiens*], anticuerpo monoclonal humanizado;
cadena pesada gamma1 [VH humanizado (*Homo sapiens* IGHV3-23*04 (87.60%) -(IGHD)-IGHJ4*01) [8.8.5] (1-112) -*Homo sapiens* IGHG1*01 (113-442)], (215-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (221-221":224-224")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYSMSWVRQA PGKGLELVAQ  50
INSVGNSTYY PDTVKGRFTI SRDNAKNTLY LQMNSLRAED TAVYYCASGD 100
YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT 150
VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT QTYICNVNHK 200
PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR 350
DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK         442
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTLGQPAS ISCRSSQSLI YSDGNAYLHW FLQKPGQSPR  50
LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHVP 100
WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    139-195   256-316   362-420
         22"-96"  139"-195" 256"-316" 362"-420"
Intra-L  23'-93'   139'-199'
         23'"-93'" 139'"-199'"
Inter-H-L  215-219'  215"-219'"
Inter-H-H  221-221"  224-224"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

```
H VH CDR2-IMGT N63:
56, 56"
H CH2 N84.4:
292, 292"
```

Recommended International Non Proprietary Names (Rec. INN): List 64
Dénominations communes internationales recommandées (DCI Rec.): Liste 64
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 64
(WHO Drug Information, Vol. 23, No. 4, 2009)

p. 264 & 265 **dalotuzumabum #**

dalotuzumab *replace the description and the structure by the following ones*
dalotuzumab *remplacer la description et la structure par les suivantes*
dalotuzumab *sustitúyase la descripción y la estructura por las siguientes*

immunoglobulin G1-kappa, anti-[*Homo sapiens* IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221], humanized monoclonal antibody;
gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV4-61*08 (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (226-226":229-229")-bisdisulfide dimer

immunoglobuline G1-kappa, anti-[*Homo sapiens* IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline (IGF1-R, IGF-1R, CD221)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV4-61*08 (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (226-226":229-229")-bisdisulfure

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IGF1R (receptor del factor de crecimiento similar a la insulina 1 (IGF1-R, IGF-1R, CD221)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV4-61*08 (86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -*Homo sapiens* IGHG1*03 (118-447)], (220-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSETLSL TCTVSGYSIT GGYLWNWIRQ PPGKGLEWIG  50
YISYDGTNNY KPSLKDRVTI SRDTSKNQFS LKLSSVTAAD TAVYYCARYG 100
RVFFDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPLS LPVTPGEPAS ISCRSSQSIV HSNGNTYLQW YLQKPGQSPQ  50
LLIYKVSNRL YGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP 100
WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    144-200    261-321    367-425
         22"-96"  144"-200"  261"-321"  367"-425"
Intra-L  23'-93'   139'-199'
         23'"-93'" 139'"-199'"
Inter-H-L  220-219'  220"-219'"
Inter-H-H  226-226"  229-229"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

```
H CH2 N84.4
297, 297"
```

Recommended International Non Proprietary Names (Rec. INN): List 67
Dénominations communes internationales recommandées (DCI Rec.): Liste 67
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
(WHO Drug Information, Vol. 26, No. 1, 2012)

p. 70 **lipegfilgrastimum #**

lipegfilgrastim *replace the description and the structure by the following ones*
lipegfilgrastim *remplacer la description et la structure par les suivantes*
lipegfilgrastim *sustitúyase la descripción y la estructura por las siguientes*

pegylated granulocyte colony stimulating factor (human short isoform); $O^{3.137}$-[{3,5-dideoxy-5-[(*N*-{[ω-methoxypoly(oxyethylene)]carbonyl}glycyl)amino]-D-*glycero*-α-D-*galacto*-non-2-ulopyranosylonic acid}-(2→6)-2-(acetylamino)-2-deoxy-α-D-galactopyranosyl]-des-(37-39)-[1-methionine]human granulocyte colony-stimulating factor (G-CSF, pluripoietin)

facteur de stimulation de colonie de granulocytes (isoforme court humain) pégylé; $O^{3.137}$-[{acide 3,5-didéoxy-5-[(*N*-{[ω-méthoxypoly(oxyéthylène)]carbonyl}glycyl)amino]-D-*glycéro*-α-D-*galacto*-non-2-ulopyranosylonique}-(2→6)-2-(acétylamino)-2-déoxy-α-D-galactopyranosyl]-dès-(37-39)-[1-méthionine]facteur humain de stimulation de colonie de granulocytes (G-CSF, pluripoïétine)

factor de estimulacin de colonías de granulocitos (isoformo corto humano) pegilado; $O^{3.137}$-[{ácido 3,5-didesoxi-5-[(*N*-{[ω-metoxipoli(oxietileni)]carbonil}glicil)amino]-D-*glicero*-α-D-*galacto*-non-2-ulopiranosilonico}-(2→6)-2-(acetilamino)-2-desoxi-α-D-galactopiranosil]-dès-(37-39)-[1-metionina]factor humano de estimulación de colonías de granulocitos (G-CSF, pluripoyetina)

```
MTPLGPASSL PQSFLLKCLE QVRKIQGDGA ALQEKL---C ATYKLCHPEE 50
LVLLGHSLGI PWAPLSSCPS QALQLAGCLS QLHSGLFLYQ GLLQALEGIS 100
PELGPTLDTL QLDVADFATT IWQQMEELGM APALQPTQGA MPAFASAFQR 150
RAGGVLVASH LQSFLEVSYR VLRHLAQP                       178
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
40-46 68-78

Modified residues / Résidu modifié / Residuo modificado



Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.